PubRank

Michael J Rogers

Author PubWeight™ 68.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006 2.73
2 Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006 2.67
3 Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007 2.15
4 Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007 2.04
5 Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 2006 1.80
6 Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 2012 1.66
7 The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 2009 1.63
8 Bone remodelling at a glance. J Cell Sci 2011 1.62
9 2.6-Million-year-old stone tools and associated bones from OGS-6 and OGS-7, Gona, Afar, Ethiopia. J Hum Evol 2003 1.56
10 Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2008 1.51
11 Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2003 1.46
12 Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008 1.41
13 Cutmarked bones from Pliocene archaeological sites at Gona, Afar, Ethiopia: implications for the function of the world's oldest stone tools. J Hum Evol 2005 1.40
14 Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010 1.39
15 Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002 1.38
16 Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008 1.37
17 Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006 1.37
18 Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest 2007 1.29
19 Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008 1.25
20 Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007 1.24
21 Technological variation in the earliest Oldowan from Gona, Afar, Ethiopia. J Hum Evol 2010 1.22
22 Fluorescently labeled risedronate and related analogues: "magic linker" synthesis. Bioconjug Chem 2008 1.22
23 Landscape-scale variation in hominin tool use: Evidence from the Developed Oldowan. J Hum Evol 2008 1.21
24 A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 2010 1.21
25 The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003 1.20
26 The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010 1.18
27 Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006 1.14
28 Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 2005 1.13
29 The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases 2011 1.11
30 Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway. Blood 2005 1.10
31 The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5. Endocrinology 2007 1.03
32 Early Pliocene hominids from Gona, Ethiopia. Nature 2005 1.01
33 Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 2003 1.00
34 Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun 2002 0.99
35 Activation of γδ T cells by bisphosphonates. Adv Exp Med Biol 2010 0.99
36 The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009 0.99
37 Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. J Biol Chem 2008 0.96
38 Raw material selectivity of the earliest stone toolmakers at Gona, Afar, Ethiopia. J Hum Evol 2005 0.95
39 Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res 2008 0.94
40 Synthesis and characterization of novel fluorescent nitrogen-containing bisphosphonate imaging probes for bone active drugs. Phosphorus Sulfur Silicon Relat Elem 2011 0.91
41 Functional interaction between sequestosome-1/p62 and autophagy-linked FYVE-containing protein WDFY3 in human osteoclasts. Biochem Biophys Res Commun 2010 0.91
42 RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009 0.91
43 The mesenchymal stem cell marker CD248 (endosialin) is a negative regulator of bone formation in mice. Arthritis Rheum 2012 0.86
44 Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002 0.85
45 Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009 0.85
46 A class III semaphorin (Sema3e) inhibits mouse osteoblast migration and decreases osteoclast formation in vitro. Calcif Tissue Int 2012 0.84
47 Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem 2010 0.84
48 Signal peptide mutations in RANK prevent downstream activation of NF-κB. J Bone Miner Res 2011 0.83
49 New evidence for hominin carcass processing strategies at 1.5 Ma, Koobi Fora, Kenya. J Hum Evol 2008 0.82
50 A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int 2007 0.82
51 Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res 2006 0.80
52 JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998). J Bone Miner Res 2005 0.79
53 Isolation and purification of rabbit osteoclasts. Methods Mol Med 2003 0.79
54 Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Pharmacol Exp Ther 2007 0.79
55 Isolation and purification of rabbit osteoclasts. Methods Mol Biol 2012 0.78
56 Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer 2011 0.78
57 Impaired prenylation of Rab GTPases in the gunmetal mouse causes defects in bone cell function. Small GTPases 2011 0.78
58 Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors. Eur J Med Chem 2011 0.76
59 Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone 2010 0.76
60 The gunmetal mouse reveals Rab geranylgeranyl transferase to be the major molecular target of phosphonocarboxylate analogues of bisphosphonates. Bone 2011 0.75
61 In vitro time- and dose-effect response of JP-8 and S-8 jet fuel on alveolar type II epithelial cells of rats. Toxicol Ind Health 2010 0.75